Literature DB >> 17534732

Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.

Mingxin Wei1, Joanne M Bargman, Dimitrios G Oreopoulos.   

Abstract

BACKGROUND: The present study was aimed at investigating the factors related to hypo-responsiveness to erythropoietin in patients on chronic peritoneal dialysis (PD).
METHODS: We studied 44 patients with end-stage renal disease who had been on PD for more than 6 months and on erythropoietin (EPO) >/=6,000 U/week for more than 3 months. We expressed EPO resistance index (ERI) as weekly EPO dose per hematocrit (Hct) per body weight. The dose of EPO was titrated to maintain a target Hct level between 33% and 36%. Patients were divided into two groups according to weekly EPO dose. We compared the various factors in those two groups and, by using correlation and linear regression analysis, investigated factors that might predict EPO resistance.
RESULTS: There were 13 patients in the EPO <150 U/kg per week group and 31 patients in the EPO >/=150 U/kg per week group. Among those 31 patients, there were five patients on EPO >/=300 U/kg per week. Compared to the EPO <150 U/kg per week group, the EPO >/=150 U/kg per week group had a lower normalized protein catabolic rate (nPCR), lower level of serum albumin and higher C-reactive protein (CRP). Correlation analysis showed that the ERI had a statistically significant correlation with CRP (r = 0.303, P < 0.05), serum albumin (r = -0.26, P < 0.05), parathyroid hormone (PTH) (r = -0.307, P < 0.05) and nPCR (r = -0.259, P < 0.05). These results show that CRP, serum albumin, PTH and nPCR are factors related to hypo-responsiveness. Multiple stepwise linear regression analysis showed that CRP was the most important independent predictor of EPO hypo-responsiveness.
CONCLUSION: CRP, serum albumin, nPCR and PTH are factors related to hypo-responsiveness. Inflammation contributes significantly to EPO hypo-responsiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534732     DOI: 10.1007/s11255-007-9226-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

Review 1.  R-HuEPO hyporesponsiveness--who and why?

Authors:  T B Drüeke
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

2.  Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure.

Authors:  S Mandolfo; F Malberti; M Farina; G Villa; R Scanziani; M Surian; E Imbasciati
Journal:  Nephrol Dial Transplant       Date:  1998-10       Impact factor: 5.992

3.  High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.

Authors:  P Bárány; J C Divino Filho; J Bergström
Journal:  Am J Kidney Dis       Date:  1997-04       Impact factor: 8.860

4.  Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.

Authors:  E Movilli; G C Cancarini; R Zani; C Camerini; M Sandrini; R Maiorca
Journal:  Nephrol Dial Transplant       Date:  2001-01       Impact factor: 5.992

5.  [Epoetin-induced pure red-cell aplasia].

Authors:  A V Kharagjitsingh; F W Dekker; J P Vandenbroucke
Journal:  Ned Tijdschr Geneeskd       Date:  2004-12-18

6.  Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.

Authors:  Francesco Locatelli; Simeone Andrulli; Bruno Memoli; Camilla Maffei; Lucia Del Vecchio; Stefano Aterini; Walter De Simone; Antonella Mandalari; Giuliano Brunori; Marcello Amato; Bruno Cianciaruso; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2005-12-29       Impact factor: 5.992

7.  Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.

Authors:  Hidetomo Nakamoto; Yoshihiko Kanno; Hirokazu Okada; Hiromichi Suzuki
Journal:  Adv Perit Dial       Date:  2004

Review 8.  Resistance to recombinant human erythropoietin therapy: a real clinical entity?

Authors:  J C Stivelman
Journal:  Semin Nephrol       Date:  1989-03       Impact factor: 5.299

9.  Increased need of erythropoietin during peritonitis in children on continuous peritoneal dialysis.

Authors:  O Amon; H Altrogge; M Kemper; J Strehlau; D E Müller-Wiefel
Journal:  Adv Perit Dial       Date:  1994

10.  Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.

Authors:  J Gunnell; J Y Yeun; T A Depner; G A Kaysen
Journal:  Am J Kidney Dis       Date:  1999-01       Impact factor: 8.860

View more
  14 in total

1.  Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.

Authors:  Uyen Duong; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Joshua J Zaritsky; Isaac Teitelbaum; Csaba P Kovesdy; Rajnish Mehrotra
Journal:  Am J Nephrol       Date:  2012-01-26       Impact factor: 3.754

2.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

Review 3.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

4.  Associations between nutritional markers and inflammation in hemodialysis patients.

Authors:  Franciele D Vannini; Aline A Antunes; Jacqueline C T Caramori; Luis C Martin; Pasqual Barretti
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

5.  Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines.

Authors:  Hadja Fatima Tbahriti; Djamel Meknassi; Rachid Moussaoui; Amar Messaoudi; Lakhdar Zemour; Abbou Kaddous; Malika Bouchenak; Khedidja Mekki
Journal:  World J Nephrol       Date:  2013-05-06

6.  Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Bernard Canaud; Lin Tong; Francesca Tentori; Takashi Akiba; Angelo Karaboyas; Brenda Gillespie; Tadao Akizawa; Ronald L Pisoni; Juergen Bommer; Friedrich K Port
Journal:  Clin J Am Soc Nephrol       Date:  2011-07       Impact factor: 8.237

7.  Secondary hyperparathyroidism and anemia in children treated by hemodialysis.

Authors:  Lorie B Smith; Jeffrey J Fadrowski; Chanelle J Howe; Barbara A Fivush; Alicia M Neu; Susan L Furth
Journal:  Am J Kidney Dis       Date:  2010-02       Impact factor: 8.860

Review 8.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

9.  Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Joshua J Zaritsky; Parta Hatamizadeh; Jennie Jing; Keith C Norris; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

10.  Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients.

Authors:  Kristin Danielson; Soheir Beshara; Abdul Rashid Qureshi; Olof Heimbürger; Bengt Lindholm; Magnus Hansson; Britta Hylander; Guna Germanis; Peter Stenvinkel; Peter Barany
Journal:  Clin Kidney J       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.